Rochester, MN Clinical Trials Report — June 2026

For Rochester residents considering participation in clinical research, June 2026 presents a mix of urgent opportunities and new avenues for contributing to medical science. With a number of trials nearing their enrollment deadlines, prompt action is essential for interested individuals.

Act Now: Trials Nearing Conclusion

A total of 66 clinical trials in Rochester are slated to conclude within the next 90 days. This urgency is particularly relevant for healthy volunteers, as 9 of these rapidly closing studies are still actively seeking participants without specific health conditions. These trials offer a chance to contribute to medical advancements before their enrollment windows close.

Patients managing specific health conditions also face impending deadlines to join research. Trials focused on various conditions are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Atrial fibrillation (3 trials)
• Ulcerative colitis (3 trials)
• Obesity (2 trials)
• Healthy (2 trials)
• Stroke (2 trials)
• Anatomic stage IV breast cancer AJCC V8 (1 trial)
• Anatomic stage III breast cancer AJCC V8 (1 trial)
• Advanced solid tumor (1 trial)
• Atrial arrhythmia (1 trial)
• Anatomic stage II breast cancer AJCC V8 (1 trial)

New Research Horizons in Rochester

This month, Rochester saw the opening of 12 new clinical trials, a slight decrease from the 16 trials that launched in May 2026. This brings the total number of actively recruiting clinical trials in Rochester, MN, to 1,120 across 134 research facilities, underscoring the city's robust research landscape.

The majority of new trials this month are either drug studies or categorized as "OTHER" research, each accounting for 5 new trials. Device trials contribute 3 new studies, while behavioral and diagnostic test trials also opened. This indicates a broad approach to medical innovation in Rochester.

Spotlight on Cutting-Edge Studies

June brings several notable new trials to Rochester, including significant Phase 2 studies from major sponsors. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic approaches across a range of health challenges.

• Mayo Clinic is sponsoring NCT07670520, "Acute Kidney Injury In Care Transitions (ACT): Pragmatic Clinical Trial." This study aims for 2,260 participants to determine the effect of a multidisciplinary intervention at care transitions for acute kidney injury survivors on patient-centered outcomes.
• Also from Mayo Clinic, NCT07670117, "HAIQU (Hospital AIr QUality)," seeks 850 participants. This research will assess whether integrating an aerosol biosensor and air quality risk assessment software into a building management system can improve indoor air quality in hospital environments and reduce respiratory disease risk factors.
• Another study sponsored by Mayo Clinic is NCT07653555, "Cascade Testing In Identifying At-risk Family Members Of Individuals With Familial Hypercholesterolemia (FH) In PCP," with 480 participants. The purpose of this study is to evaluate the effectiveness of two models of cascade testing in identifying at-risk family members of individuals diagnosed with familial hypercholesterolemia (FH).
• Mayo Clinic is also leading a Phase 2 trial, NCT07650240, "Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE Trial," with 202 participants. This trial tests leuprolide acetate alone versus in combination with 177Lu-PSMA-617, with or without abiraterone acetate and prednisone, for hormone-sensitive prostate cancer that has spread to a limited number of sites.
• Washington University School of Medicine is sponsoring a Phase 2 study, NCT07620548, "Laser Interstitial Thermal Therapy (LiTT) With Cemiplimab or Other Chemotherapy in Recurrent Glioblastomas," involving 99 participants. This study will assess the therapeutic efficacy of combining Laser Interstitial Thermal Therapy (LiTT) with adjuvant cemiplimab compared to LiTT with physician's choice of adjuvant chemotherapy in patients with recurrent glioblastoma.
• From Aurigene Discovery Technologies Limited, a Phase 2 study, NCT07640737, "AUR103 Calcium in Advanced Neuroendocrine Tumours (BHARAT-3 Study)," is recruiting 30 participants. This Proof of Concept (PoC) study evaluates the efficacy and safety of single agent AUR103 calcium in patients with advanced, well or moderately differentiated neuroendocrine tumors.

Diverse Conditions Under Investigation

New trials this month are exploring a range of conditions, offering opportunities for patients with specific health needs. Conditions with new trials include:

• Acute kidney injury (1 trial)
• Acute respiratory tract infection (1 trial)
• Adenocarcinoma of the prostate (1 trial)
• Advanced cancer (1 trial)
• Advanced NET of GI origin (1 trial)
• Advanced prostate adenocarcinoma (1 trial)
• Advanced prostate cancer (1 trial)
• Back pain (1 trial)
• Cardiovascular disease (1 trial)
• Cardiogenic pulmonary oedema (1 trial)

Opportunities for Healthy Volunteers

For individuals without a specific medical condition, there are significant opportunities to contribute to research. Of the 12 new trials launched this month, 1 is actively seeking healthy volunteers. Across Rochester, a total of 120 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Rochester's Leading Research Hubs

Rochester is home to some of the nation's leading research institutions, which consistently run a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• Mayo Clinic (429 trials)
• Mayo Clinic in Rochester (350 trials)
• Mayo Clinic Rochester (75 trials)
• Mayo Clinic - Rochester (31 trials)
• Research Site (30 trials)
• Mayo Clinic Minnesota (20 trials)
• Mayo Clinic, Rochester (12 trials)
• Mayo Clinic in Rochester, Minnesota (11 trials)
• Mayo Clinic Cancer Center (6 trials)
• Clinical Trial Site (6 trials)
• Mayo Clinic in Minnesota (5 trials)
• Mayo Clinic (Data Collection Only) (4 trials)

These institutions, particularly the various Mayo Clinic facilities, offer a broad spectrum of research, making Rochester a significant center for medical advancement.

Beyond Rochester: Expanding Your Search

While Rochester offers a vast array of clinical trial opportunities, individuals may also find options in nearby communities within Minnesota. Cities with active trials include Minneapolis (10 trials), Mankato (3 trials), Duluth (1 trial), Richfield (1 trial), Saint Louis Park (1 trial), and Saint Paul (1 trial).

Who Can Participate?

Participation in clinical trials is open to a diverse range of individuals. Of the 12 new trials launched this month, 11 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 2 new trials include children, 1 is female-only, and 1 is male-only. Academic institutions continue to play a vital role in Rochester's research ecosystem, with Mayo Clinic sponsoring 9 of the new studies. Industry sponsors like Aurigene Discovery Technologies Limited and academic partners like Washington University School of Medicine are also driving significant research efforts.

As we move through June, Rochester's robust research community will continue to drive medical innovation, offering diverse opportunities for individuals to contribute to the future of healthcare.